The exogenous administration of IGF-1, at low doses (similar to those used in the present work), restored IGF-1 serum levels reducing dyslipidemia and insulin resistance, oxidative liver damage and mitochondrial dysfunction [7, 51]. The gene discussed is IGF1; the disease is metabolic syndrome.